- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02970084
Vitamin K2 for Reduction the Calcium at Carotid Bifurcation in Patients With Subcritical Lesions
May 21, 2019 updated by: yamume tshomba, Scientific Institute San Raffaele
Role of Vitamin K2 in the Reduction of the Calcium Content at the Level of the Carotid Bifurcation in Patients With Subcritical Lesions
Clinical study single center, prospective, randomized, controlled (vs.
no supplement), open-label, blinded assessor (the doctor who will perform the Doppler ultrasound at 6 and 12 months will not know the treatment given to the patient, because the diagnostic test in question is considered operator-dependent), a "parallel group", which aims is evaluate the reduction in the level of calcium in the carotid artery and the carotid atherosclerotic plaques, on a sample of 60 subjects presenting subcritical calcified lesions of the carotid bifurcation with a range of 40-60%.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Milano, Italy, 20132
- San Raffaele Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age ≥ 18 years
- Ability to provide written informed consent
- subjects with calcified lesions subcritical from the carotid bifurcation. with a range of 40-60% calculated method with ECTS (European Carotid Surgery Trial)
Exclusion Criteria:
- Patients with reduced life expectancy or age> 80 years,
- Patients already subjected to other clinical trial in the previous three months,
- Patients with hypersensitivity or with known allergies to acetylsalicylic acid, patients with pre-existing mastocytosis, a history of asthma induced by salicylates, duodenal ulcer, bleeding diathesis, severe hepatic insufficiency, severe heart failure, concomitant treatment with methotrexate, last trimester of pregnancy.
- Patients with known hypersensitivity to vitamin K2 and vitamin D, people with hemolytic diseases, concomitant anticoagulant therapy, people with cancer, MAV (arteriovenous malformations) and / or cerebral aneurysms, hypercalcemia, nephrolithiasis and renal failure.
- Uncooperative patients , or allergies related to the substance under study or with any contra-indicated in the data sheet / Summary of Product Characteristics (SPC) of the substances in the studio.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group with K2
The nutraceutical product (PLAK2) based on vitamin K2, will be administered once a day (a tablet 800mg) for 12 months. All patients enrolled will continue to be treated according to the clinical standard (100 mg Cardioaspirin, cp 1 day : Acetylsalicylic acid) |
Other Names:
|
No Intervention: Control group (no vitamin K2)
The control group did not take the supplement of Vitamin K2.
All patients enrolled will continue to be treated according to the clinical standard (100 mg Cardioaspirin, cp 1 day : Acetylsalicylic acid)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Reduction of calcium content, to 12 months, at the level of carotid atheromatous plaque
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2016
Primary Completion (Actual)
May 1, 2019
Study Completion (Actual)
May 1, 2019
Study Registration Dates
First Submitted
November 18, 2016
First Submitted That Met QC Criteria
November 18, 2016
First Posted (Estimate)
November 21, 2016
Study Record Updates
Last Update Posted (Actual)
May 23, 2019
Last Update Submitted That Met QC Criteria
May 21, 2019
Last Verified
May 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PLAK2/74/OSR
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carotid Plaques
-
Ziv HospitalUnknownCarotid Artery StenosisIsrael
-
Papworth Hospital NHS Foundation TrustUnknown
-
University of Lausanne HospitalsSwiss Heart FoundationRecruitingInflammation | Carotid Artery Diseases | Atheromatous PlaquesSwitzerland
-
Assistance Publique - Hôpitaux de ParisNational Research Agency, FranceRecruitingCarotid Atherosclerosis | Acute Myocardial Infarction | Severe PeriodontitisFrance
-
Rush University Medical CenterIcahn School of Medicine at Mount SinaiWithdrawnMyocardial Infarction | Myocardial Ischemia | Heart Diseases | Coronary Artery Disease | Stroke | Cerebrovascular Disorders | Coronary Disease | Arteriosclerosis | Arterial Occlusive Diseases | Cardiovascular Disease | Atherosclerosis | Peripheral Vascular Disease | Cerebral Infarction | Coronary Arteriosclerosis | Cerebrovascular... and other conditions
-
Erasmus Medical CenterRecruitingChest Pain | Epicardial PlaquesNetherlands
-
Mahidol UniversityCompleted
-
Silk Road MedicalCompletedCarotid Artery Plaque | Carotid Stenosis | Carotid Artery Diseases | Carotid Atherosclerosis | Carotid DiseaseUnited States, Spain
-
University of HelsinkiUniversity of Eastern FinlandCompleted
-
Xuanwu Hospital, BeijingRecruitingCarotid Artery Plaque | Carotid Artery Stenting | Carotid EndarterectomyChina
Clinical Trials on Nutraceutical product based on vitamin K2 (PLAK2)
-
Denver Health and Hospital AuthorityHaemonetics CorporationCompletedAcute CoagulopathyUnited States
-
St. Jude Children's Research HospitalRecruitingCytomegalovirus | AdenovirusUnited States
-
BonusBio Group LtdCompletedBone Void in the Maxillofacial AreaIsrael
-
McGill UniversityGlobal Affairs Canada; World Vision CanadaNot yet recruitingStunting | Diet; Deficiency | Empowerment | Acceptability of Health Care | Gender EqualityBangladesh, Kenya, Tanzania